Secukinumab and Ixekizumab bind to IL-17A and achieved excellent therapeutic efficacy and safety in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.49 50 Therefore, in a further clinical trial, it is necessary to fully implement this combination of anti-IL-17A and anti-PD-1 in the treatment of patients with MSS CRC. Here, IL17A is linked to psoriatic arthritis.